Hemanext
Lexington, US · Delaware corporation
Hemanext develops oxygen-controlled storage technology to preserve red blood cell quality and function during transfusion storage. The company serves hospitals and blood establishments seeking to improve patient outcomes in transfusion medicine.
Founders & leadership
MC
Martin CannonFounder and former CEO
JB
Jill BuckleyinVice President of Human Resources
DK
Daan KokinHead of Business Development and Strategy
RH
Robert HaimeinVice President of Commercial Operations
RC
Rafael CorderoinVice President, Product Development
MB
Michael BavoneseinExecutive
AD
Andrew DunhamNamed on SEC filing
Board
SE
Stephen EckertChairman of the Board of Directors
PP
Philip PeadBoard director
GC
Geoffrey CrouseBoard director
WP
William Patrick O'NeillBoard director
EA
Eduardo AvayuBoard director
Reported raises · per SEC filings
Form D private placements$122.3M disclosed across 8 of 9 rounds · 2016–2025
▶$20MraisedAug 2025 · 29 investors · Other Health CareRule 506(b)
▶$20MraisedAug 2025 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert HaimeExecutive Officer
- Eric J. NewmanExecutive Officer
- Peter TestaDirector
- Daan KokExecutive Officer
- Paul M. NessDirector
- Geoffrey CrouseDirector
- Andrew DunhamExecutive Officer, Director
- Laura DanielsExecutive Officer
- Eduardo AvayuDirector
- Philip PeadDirector
- Stephen A. EckertDirector
- Joseph GroganDirector
- Laurel OmertExecutive Officer
- Ismail KolaDirector
- William Patrick O'NeillDirector
- Jill BuckleyExecutive Officer
- Offering amount
- $24M
- Amount sold
- $20M
- Sales commissions
- $41.3K
- Placement agents
- Octavian AG
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.7MraisedJul 2025 · 51 investors · Other Health CareRule 506(b)
▶$21.7MraisedJul 2025 · 51 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stephen A. EckertDirector
- Philip PeadDirector
- Geoffrey CrouseDirector
- William Patrick O'NeillDirector
- Jill BuckleyExecutive Officer
- Eduardo AvayuDirector
- Peter TestaDirector
- Daan KokExecutive Officer
- Robert HaimeExecutive Officer
- Paul M. NessDirector
- Ismail KolaDirector
- Andrew DunhamExecutive Officer, Director
- Eric J. NewmanExecutive Officer
- Joseph GroganDirector
- Laura DanielsExecutive Officer
- Laurel OmertExecutive Officer
- Offering amount
- $21.7M
- Amount sold
- $21.7M
- Sales commissions
- $27.2K
- Placement agents
- Octavian AG
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedJan 2024 · 10 investors · Other Health CareRule 506(b)
▶$5MraisedJan 2024 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stephen A. EckertDirector
- Paul M. NessDirector
- Andrew DunhamExecutive Officer, Director
- Robert HaimeExecutive Officer
- Laurel OmertExecutive Officer
- Michael David TestaDirector
- Laura DanielsExecutive Officer
- Daan KokExecutive Officer
- William Patrick O'NeillDirector
- Eduardo AvayuDirector
- Ismail KolaDirector
- Eric J. NewmanExecutive Officer
- Jill BuckleyExecutive Officer
- Richard PerleDirector
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.3MraisedNov 2023 · 20 investors · Other Health CareRule 506(b)
▶$11.3MraisedNov 2023 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jill BuckleyExecutive Officer
- Andrew DunhamExecutive Officer, Director
- William Patrick O'NeillDirector
- Daan KokExecutive Officer
- Laurel OmertExecutive Officer
- Laura DanielsExecutive Officer
- Ismail KolaDirector
- Richard PerleDirector
- Eduardo AvayuDirector
- Stephen A. EckertDirector
- Robert HaimeExecutive Officer
- Paul M. NessDirector
- Eric NewmanExecutive Officer
- Michael David TestaDirector
- Offering amount
- $11.3M
- Amount sold
- $11.3M
- Finders' fees
- $400K
- Placement agents
- Sonenshine & Company LLC
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.2MraisedFeb 2023 · 38 investors · Other Health CareRule 506(b)
▶$13.2MraisedFeb 2023 · 38 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Martin A. CannonExecutive Officer, Director
- Daan KokExecutive Officer
- Eric NewmanExecutive Officer
- Michael David TestaDirector
- Guy CoganDirector
- Andrew DunhamExecutive Officer
- William Patrick O'NeillDirector
- Kimberly DorschExecutive Officer
- Jill BuckleyExecutive Officer
- Ismail KolaDirector
- Eduardo AvayuDirector
- Richard PerleDirector
- Robert HaimeExecutive Officer
- Paul M. NessDirector
- Alex MarichalExecutive Officer
- Stephen EckertDirector
- Laurel OmertExecutive Officer
- Laura DanielsExecutive Officer
- Offering amount
- $15M
- Amount sold
- $13.2M
- Finders' fees
- $1.1M
- Placement agents
- Sonenshine & Company LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$39.6MraisedOct 2021 · 39 investors · BiotechnologyRule 506(b)
▶$39.6MraisedOct 2021 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric NewmanExecutive Officer
- Guy CoganDirector
- Laura DanielsExecutive Officer
- Michael David TestaDirector
- William Patrick O'NeillDirector
- Andrew DunhamExecutive Officer
- Laurel OmertExecutive Officer
- Eduardo AvayuDirector
- Stephen EckertDirector
- Richard PerleDirector
- Jill BuckleyExecutive Officer
- Robert HaimeExecutive Officer
- Alex MarichalExecutive Officer
- Paul M. NessDirector
- Martin A. CannonExecutive Officer, Director
- Offering amount
- $59.5M
- Amount sold
- $39.6M
- Finders' fees
- $1.1M
- Placement agents
- Sonenshine & Company LLC
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.8MraisedOct 2018 · 6 investors · BiotechnologyRule 506(b)
▶$8.8MraisedOct 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard PerleDirector
- Martin A. CannonExecutive Officer, Director
- Stephen EckertDirector
- Guy CoganDirector
- David HermanDirector
- Eric NewmanExecutive Officer
- Michael David TestaDirector
- Joseph BarrettExecutive Officer
- Offering amount
- $16M
- Amount sold
- $8.8M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedDec 2017 · 6 investors · BiotechnologyRule 506(b)
▶$2.7MraisedDec 2017 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin A. CannonExecutive Officer, Director
- Michael David TestaDirector
- David HermanDirector
- Lynn MallettExecutive Officer
- Joseph BarrettExecutive Officer
- Guy CoganDirector
- Stephen EckertDirector
- Richard PerleDirector
- Offering amount
- $5M
- Amount sold
- $2.7M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapGlobaldata10 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Baidu6 shared keywordsChina's leading search engine and AI technology company
Companies competing with Hemanext for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Hemanext do?
- Hemanext develops oxygen-controlled storage technology to preserve red blood cell quality and function during transfusion storage. The company serves hospitals and blood establishments seeking to improve patient outcomes in transfusion medicine.
- Who founded Hemanext?
- Hemanext was founded by Martin Cannon.
- How much funding has Hemanext raised?
- Hemanext has disclosed $122.3M raised across 8 of its 9 known rounds.
- Where is Hemanext headquartered?
- Hemanext is headquartered in Lexington, US.